Slocum, Gordon & Co’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.08M Sell
20,187
-280
-1% -$60.2K 3.37% 8
2026
Q1
$4.45M Sell
20,467
-555
-3% -$123K 3.03% 10
2025
Q4
$4.8M Sell
21,022
-87
-0.4% -$19.8K 3.48% 9
2025
Q3
$4.89M Sell
21,109
-37
-0.2% -$7.54K 3.9% 9
2025
Q2
$3.93M Sell
21,146
-254
-1% -$47.2K 3.16% 11
2025
Q1
$4.48M Sell
21,400
-16,917
-44% -$3.29M 3.34% 11
2024
Q4
$6.81M Sell
38,317
-1,857
-5% -$341K 5.6% 5
2024
Q3
$7.93M Sell
40,174
-2,282
-5% -$426K 3.19% 9
2024
Q2
$7.28M Sell
42,456
-58
-0.1% -$9.61K 5.42% 6
2024
Q1
$7.74M Sell
42,514
-30
-0.1% -$5.17K 5.75% 5
2023
Q4
$6.59M Buy
42,544
+250
+0.6% +$36.4K 5.79% 5
2023
Q3
$6.3M Sell
42,294
-850
-2% -$125K 5.49% 5
2023
Q2
$5.81M Sell
43,144
-260
-0.6% -$38.1K 4.22% 10
2023
Q1
$6.92M Sell
43,404
-12,850
-23% -$1.96M 5.74% 6
2022
Q4
$9.09M Buy
+56,254
New +$8.63M 5.86% 6

Other funds holding ABBV

Slocum, Gordon & Co's ABBV Position: Q2 2026 in Review

Slocum, Gordon & Co reduced its AbbVie (ABBV) stake by 1.4% in Q2 2026, selling an estimated $60.2K and leaving 20,187 shares worth $5.08M. The position accounts for 3.37% of the portfolio, ranked #8.

Slocum, Gordon & Co first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. The position peaked at $9.09M in Q4 2022. 1,743 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Slocum, Gordon & Co held 20,187 shares of AbbVie worth $5.08M as of Q2 2026.
  • Slocum, Gordon & Co sold 280 AbbVie shares in Q2 2026, an estimated $60.2K.
  • AbbVie made up 3.37% of Slocum, Gordon & Co's portfolio in Q2 2026, its #8 holding.
  • Slocum, Gordon & Co first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • Slocum, Gordon & Co's AbbVie position peaked at $9.09M in Q4 2022.
  • 1,743 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Slocum, Gordon & Co's 13F filing for Q2 2026, filed 23 Jul 2026.